FBLG stock news · FibroBiologics
Get alerts for FBLG
Follow FibroBiologics (FBLG) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FBLG12 health care stocks changed a lot in prices after the market closed on Tuesday.
NeutralFibroBiologics shares rose about 9% after hours. The article gives no business reason for the move, so it does not change what we know about the company.
FibroBiologics, Inc. has signed an important deal with Peak One Opportunity Fund, L.P.
Bad for FBLGFibroBiologics received $1.02 million in financing, but must pay $1.08 million in April 2027. The repayment burden makes this unfavorable for the company.
FibroBiologics has applied for a patent for a new cell-based treatment that could replace GLP-1 shots.
Good for FBLGFibroBiologics filed a patent application for cells designed to release treatment peptides inside the body. This adds a promising research path, but patient benefits remain unshown.
On Friday evening, 12 health care stocks saw big changes in their prices.
NeutralFibroBiologics' shares fell about 7% after hours, but the report gives no company news to change its business outlook.
12 health care companies saw big changes in their stock prices after the market closed on Friday.
NeutralFibroBiologics shares fell about 5% to $1.32 after hours. The report gives no new business news, so its business outlook remains unchanged.
12 health care companies saw big changes in their stock prices after the market closed on Friday.
NeutralThe report says FibroBiologics shares fell 5.0% after hours, but gives no business update to explain the move. It does not change the company's business outlook.
FibroBiologics, Inc. signs a big deal to sell shares and raise about $0.5 million.
NeutralFibroBiologics sold 298,508 shares and warrants to its CSO for about $0.5M; insider buying and the small raise roughly cancel, so I do not change how I read the company.
FibroBiologics, Inc. details leadership transitions, including the exit and election of directors and the appointment of new officers, along with their compensation arrangements (FBLG).
NeutralFibroBiologics, Inc. has filed a Form 8-K detailing significant changes in its leadership, including the departure and appointment of certain officers and directors. Such changes can lead to shifts in company strategy and investor confidence, making this news particularly relevant for stakeholders.
Preclinical findings from FibroBiologics influence the planning of additional research for degenerative joint therapy.
Good for FBLGFibroBiologics has announced promising preclinical results demonstrating effective cartilage repair through a new treatment method, which could lead to significant advancements in the management of degenerative joint diseases. This breakthrough positions the company favorably in the biotech sector, potentially attracting investor interest and enhancing its market valuation.